In HFmrEF and CAD, the first study on SGLT2 inhibitors in HFmrEF demonstrated that sotagliflozin reduced cardiac outcomes in patients with HF and type 2 diabetes, regardless of LVEF, with subsequent studies recommending SGLT2 inhibitors as primary treatment. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.